pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who have been clinically diagnosed with pancreatic cancer (including IPMC) and are planning to undergo surgery. 2. Patients undergoing initial treatment 3. Patients with a PS (ECOG classification) of 0 to 1 4. Patients with preserved function of major organs (bone marrow, liver, kidneys, lungs, etc.) 5. Patients who can take food orally 6. Patients who can use a tablet or smartphone and have a good internet connection at home 7. Patients who have given written consent to be subjects of this study 8. Adults aged 18 years or older at the time of consent acquisition who have sufficient judgment to give consent to this study 9. Patients who have received a sufficient explanation of the contents of this study and have given written consent
Exclusion criteria
Exclusion criteria: 1. Patients with pulmonary fibrosis or interstitial pneumonia 2. Patients with macroscopic residual cancer at the time of resection 3. Patients with active overlapping cancers 4. Patients with active infections 5. Patients with positive HBs antigen 6. Patients using flucytosine, phenytoin, or warfarin 7. Patients who are pregnant or may be pregnant 8. Patients who are otherwise deemed unsuitable by the attending physician to safely conduct this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient adherence to the program 6 months after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Validity (changes from baseline at 3 and 6 months in grip strength, knee extension strength, 6-minute walk, EORTC-C30, FACT-Hep, SDS, etc.) and safety (incidence of adverse events over the entire study period) | — |
Countries
Japan
Contacts
Fukushima Medical University Faculty of Nursing